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Role of diuretics in the preservation of residual renal function peritoneal dialysis (PD) as the renal removal of solutes
in patients on continuous ambulatory peritoneal dialysis. continues to provide a significant proportion of total
Background. Patients on continuous ambulatory peritoneal solute clearance even when a patient is well establisheddialysis (CAPD) are dependent on residual renal function for
on dialysis. A decline or loss of residual renal functionsolute and water clearances, and this declines with time on dial-
can make adequate PD difficult or sometimes impossible,ysis. Loop diuretics have been postulated to slow this decline.
Methods. Sixty-one patients new to dialysis were randomly particularly in patients of above-average size [1]. As a
assigned to either furosemide 250 mg every day or no furose- result, patients are at risk of underdialysis and may be
mide at the time of CAPD training and were followed prospec- forced to change dialysis modalities, with medical, social,tively. Urine volume (UV), urea clearance (CUrea), and creati-
and cost implications.nine clearance on cimetidine (CCr) were measured at random-
Residual renal function also aids the maintenance ofization at six months and at one year. Patients underwent a
standard four-hour peritoneum equilibrium test, and total body steady-state fluid balance. A greater urine volume (UV)
water was measured by bioelectrical impedance. Results were allows patients a wider freedom with regard to fluid intake
expressed on an intention-to-treat basis. and allows physicians greater opportunity for optimalResults. UV, CCr, and CUrea were similar at randomization
control of fluid balance. This is important as persistent(1020 6 104 vs. 1040 6 130 mL/24 hours, 4.95 6 0.51 vs. 4.07 6
fluid overload is thought to contribute to the accelerated0.40 mL/min/1.73 m2, 0.91 6 0.09 vs. 0.84 6 0.08, diuretic vs.
control). UV in the diuretic-treated group increased, whereas increase in cardiovascular disease seen in patients on
in the control group, it declined (1176 vs. 2200 mL/24 hours long-term dialysis. Finally, greater urinary water clear-
at 6 months and 148.8 vs. 2305 mL/24 hours at 1 year, P , ance might be expected to translate into a reduction in0.05). CCr and CUrea declined at a constant rate and were unaf-
the need for hyperosmolar glucose dialysate, which mayfected by diuretic administration (0.12 6 0.05 vs. 0.071 6 0.04
in turn assist in protecting long-term peritoneal mem-mL/min/1.73 m2/month, 0.020 6 0.01 vs. 0.019 6 0.01 per
month). Urinary sodium excretion increased in the diuretic brane function.
group and declined in the control group (10.72 6 0.85 vs. Unfortunately, longitudinal studies have shown that re-
22.56 6 1.31 mmol/24 hours/month, P 5 0.04). Body weight sidual renal function progressively declines with time onrose in both groups (4.3 vs. 3.0 kg), but the percentage of total
dialysis [2]. Most studies show that the rate of declinebody weight rose in the control group and remained constant
is slower when on CAPD than hemodialysis [3–5] at ratein the diuretic group (52 6 2.4 vs. 64 6 6.6%, P 5 0.10).
Conclusions. Long-term furosemide produces a significant of approximately 3% per month (abstract; Hallett et al,
increase in UV over 12 months when on CAPD and may result Perit Dial Int 12:124, 1992). However, after a period of
in clinically significant improvement in fluid balance. However, approximately 36 months on CAPD, the contribution offurosemide has no effect on preserving residual renal function.
residual renal function to dialysis adequacy has been
shown to be negligible [6], although others have shown
that it can make a useful contribution for much longerPatients with end-stage renal failure on continuous
[7]. Therefore, any intervention that slows the declineambulatory peritoneal dialysis (CAPD) benefit from sig-
in residual renal function in patients on PD would benificant residual renal function for successful long-term
expected to confer considerable potential benefit.
The role of loop diuretics in long-term PD is contro-
versial as there is no previous large-scale controlled trialsKey words: peritoneal dialysis, furosemide, dialysis adequacy, loop
diuretics, urine solute clearance, end-stage renal failure. on their use in PD. Large doses of furosemide (500 to
2000 mg/day) have been shown to increase UV and so-Received for publication July 7, 2000
dium and potassium excretion in patients on CAPD inand in revised form September 19, 2000
Accepted for publication September 22, 2000 short-term studies (1 to 3 days) [8, 9]. There was no
effect from diuretics if the patient passed less than 100Ó 2001 by the International Society of Nephrology
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Table 1. Demography at randomizationmL of urine per day and the scale of the naturesis was
greater in the patients with higher glomerular filtration Control Diuretic
rate (GFR). No large, prospective, long-term studies ex- Number 30 31
Median age (range) 51 (23–82) 63 (23–77)amining the effects of diuretics in CAPD patients have
Sex male/female 17/13 25/6been reported. The use of the diuretic muzolimine in six Diabetes mellitus 3 8
PD patients was reported to cause a slower decline in
UV at one year [10], but this study was not prospective
and too small to allow definite conclusions to be drawn.
Study measurementsThe aim of the current study was to investigate whe-
Baseline demographic measures were collected fromther furosemide given long term to patients on PD would
both groups at randomization, including age, sex, renalpreserve UV and/or urine solute clearance without un-
diagnosis, and predialysis biochemistry. UV was recordedwanted side effects. In addition, whether the use of di-
at randomization, 6 and 12 months by measured collec-uretics could translate into clinical improvement in fluid
tion over 24 hours. Urinary and dialytic urea and CCrstate was examined. was calculated from measured collections of urine and
spent PD solution using standard formulae. For these
measurements, patients took cimetidine to block proxi-METHODS
mal tubular creatinine secretion [11]. Cimetidine 400 mg
This prospective, randomized, open-label study was ap- was administered orally in three doses every 12 hours,
proved by the Ethical Committee of the Leicestershire with the first dose 12 hours before the collection period.
Health Authority. As it was anticipated that the patient Urinary electrolytes and osmolality were measured on
group would require frequent hospital admissions, it was the 24-hour urine collections to allow calculation of free
decided to adopt an open-label study design in order to water and electrolyte free water clearances [12]. Patients
then underwent a peritoneum equilibrium test (PET)ensure that study medication could easily be continued
using a standard protocol [13], and total body waterduring inpatient stays. Sixty-one sequential new patients
was assessed by bioelectrical impedance using a Xitronto CAPD were enrolled after obtaining written consent.
4000B (Xitron technologies Ltd., San Diego, CA, USA).Patients aged greater than 16 years starting CAPD between
A venous blood biochemical profile, including potas-June 1996 and November 1997 were recruited and each
sium, calcium, albumin, urate, lipid profile, and hemoglo-followed for one year. Patients who had previously received
bin, was obtained. Patients had a dietetic assessment
more than two weeks of hemodialysis and those with a with measurement of weight, triceps skin-fold thickness,
failing renal transplant were excluded from the study. and mid-arm circumference.
Randomization and treatment Statistical analysis
Patients were randomized 10 days after CAPD train- Prospective construction of sample size (a 5 0.05 two
sided, b 5 0.1) with a clinically significant difference ining to receive either furosemide 250 mg daily or no di-
UV of 350 mL required 25 patients in each arm of theuretic. Patients in the diuretic-treated group were addi-
study. Using this sample size, the detectable differencetionally given metolazone 5 mg daily if their UV did not
in Kt/V with the same confidence was 0.21. Predefinedexceed 500 mL/24 h at any follow-up visit. Each patient
primary outcome measures were change in UV, urinaryunderwent a study assessment at 6 and 12 months by
urea, and urinary CCr over one year. Continuous data areone physician (J.M.). All other care of both groups was
expressed as means 6 SEM. Primary outcome measures
conducted according to standard policies and procedures were shown to be normally distributed using the method
in force in our department during this time and did not of Kolmogorov-Smirnov and analyzed on an intention-
differ between the groups. Dialytic prescription was ad- to-treat basis using two-sided parametric statistics (un-
justed independent of the study and was guided by clini- paired t test) on data at one year. A mean decline in
cal parameters and calculated clearances. Local proto- UV, urinary sodium, urea, and CCr occurred in a linear
cols called for targets of creatinine clearance (CCr) manner. To allow inclusion of data at all time points for
these variables, the rate of decline was established forgreater than 65 L/week. A urea clearance (Kt/V) of
each patient by linear regression, and this single measuregreater than 1.7 per week was adopted according to that
was compared between groups using an unpaired t test.recommended at the time of the study by the British
Statistical significance was defined as P , 0.05.Renal Association. Blood pressure was measured using
an automated blood pressure device, and readings con-
RESULTSsistently above an age-adjusted target blood pressure
were controlled by reduction in target weight before Baseline demographic features of both groups are
shown in Table 1. Age range in both groups was compa-introduction of antihypertensive medication.
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tion and increased with the administration of furosemide,
whereas in the control group, it declined progressively
with time. Urinary urea and CCr declined at constant
rate over one year of CAPD and was unaffected by
furosemide administration.
Laboratory data for both groups at randomization and
one year is presented in Table 3. Hemoglobin rose in
both groups over one year of CAPD with a comparable
rate of usage of erythropoeitin. In both groups, serum
albumin, potassium, and urate were similar and un-
changed by the initiation of dialysis. Serum cholesterol
rose in both groups with time on dialysis (0.37 vs. 0.52
mmol/L, diuretic vs. control), but was not different be-
tween the groups. Urinary free water clearance is also
Fig. 1. Evolution of urine volume (UV) over one year of peritoneal summarized in Table 3. Free water clearance and electro-
dialysis (PD). UV at randomization was comparable between groups. lyte-free water clearance were calculated by standardIn the diuretic group (j), it remained constant over one year of CAPD,
methods using the ratio of serum–to–urinary osmolalitywhereas in the control group (m), UV declined. Data presented are
mean 6 SEM at each time point. or electrolyte concentration, respectively. Both groups
had similar urinary-free water clearances that did not
alter over the course of the study.
Body composition is summarized in Table 4. BodyTable 2. Change in urine volume, urinary sodium, urea and
creatinine clearance weight rose in both groups over one year of CAPD and
was not different between groups (4.3 vs. 3.0 kg, diureticControl Diuretic P value
vs. control). Total body weight measured by bioelectrical
D Urine volume mL/month 223.3611.2 16.4769.52 0.047
impedance is expressed as a percentage of body weightD 24-hour urinary sodium
mmol/24 h 22.5761.51 10.7260.85 0.041 and was comparable at randomization between groups
D Creatinine clearance (55 6 4.7 vs. 52 6 2.1%, diuretic vs. control). However,mL/min/month 20.07160.04 20.1260.05 0.45
the proportion of total body weight in the control groupD Urinary Kt/v per month 20.01960.01 20.02060.01 0.92
rose, whereas in the diuretic-treated group, it remained
constant, although the difference between the diuretic
and control groups did not reach statistical significance
rable, although the median age in the diuretic-treated (52 6 2.4 vs. 64 6 6.6%, diuretic vs. control, P 5 0.10).
group was higher. As there were a greater proportion In the control group, total body weight rose by 5.3 L
of patients with diabetes mellitus (DM) in the diuretic- over the course of the study, accounting for the gain in
treated group, a separate secondary analysis was per- weight in this group.
formed that excluded patients with DM. This analysis Both groups had similar peritoneal urea and CCr values
produced comparable results, and therefore, the results (summarized in Table 5). At randomization, both groups
for the whole group are reported. Nine patients in the had comparable 24 ultrafiltration volumes (606 6 152
diuretic-treated group and five patients from the control vs. 664 6 111 mL/24 hours). Over one year of CAPD,
group withdrew from the study (4 vs. 3 patients trans- the diuretic-treated group had a trend toward a progres-
planted, 2 vs. 1 changed to HD, 3 vs. 1 died, respectively). sive fall in ultrafiltration volume to 476 6 256 mL/
Included in the analysis are three patients in the diuretic 24 hours, whereas in the control group, it progressively
group and two in the control group who became anuric increased to 1020 6 176 mL/24 hours. There was a similar
during the course of the study. trend toward a difference in ultrafiltration volume on
Urine volume at the randomization was comparable four hours PET, although neither result reached statisti-
in both groups (1020 6 104 vs. 1040 6 130 mL/24 h, cal significance. The dialysate glucose concentration was
diuretic vs. control). Evolution in UV with time is shown similar in both groups (Table 5) and did not change
in Figure 1. Mean change in UV, urinary sodium, urea, significantly over the year of the study.
and CCr occurred in a linear manner, and hence, the rate
of change of these parameters is presented in Table 2.
DISCUSSIONAfter one year of CAPD, UV declined in the control
Successful long-term PD is dependent on adequategroup to 733 6 124 mL/24 hours, whereas in the diuretic-
solute and water clearances, which is dependent on resid-treated group, it was comparable to baseline (1070 6
ual renal function. However, residual renal function has193 mL/24 hours). Twenty-four–hour urinary sodium ex-
cretion was comparable between groups at randomiza- been shown to decline progressively with time on dialysis
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Table 3. Summary of laboratory data
Control Diuretic
Randomization 1 year Randomization 1 year
Serum
Haemoglobin g/dL 11.360.28 12.260.31 10.460.20 11.760.39
Albumin g/L 34.060.79 35.160.71 33.860.56 35.160.59
Potassium mmol/L 3.9060.10 4.0860.11 3.7960.11 4.0060.11
Urate mmol/L 329621.7 317612.5 349612.0 364623.8
Cholesterol mmol/L 5.2760.18 5.7960.21 5.4660.22 5.8360.12
Triglycerides mmol/L 1.8960.15 2.2660.38 2.1760.17 1.9660.19
Urinary water clearance
Free water clearance mL/day 204671.0 220666.2 145632.0 123662.0
Electrolyte free water clearance mL/day 378670.1 333673.4 292634.9 312678.7
Table 4. Body composition
Control Diuretic
Randomization 1 year Randomization 1 year P value
Weight kg 67.062.82 70.063.68 74.162.74 78.463.57
TSF mm 13.161.1 16.661.8 13.861.3 13.061.6
MAC cm 28.060.6 29.161.0 28.960.6 31.361.4
% TBW/body weight % 5262.4 6466.6 5564.7 5262.4 0.10
MAP mm Hg 10362.7 97.063.1 10362.2 10463.8
Abbreviations are: TSF, triceps skin-fold; MAC, mid-arm circumference; TBW, total body water.
Table 5. Peritoneal clearances, PET and dialysate composition
Control Diuretic
Randomization 1 year Randomization 1 year P value
Ultrafiltration mL/24 h 6646111 10206176 6066152 4766256 0.09
Creatinine clearance L/week 38.261.46 39.262.15 36.861.67 36.762.15 NS
Urea clearance Kt/V 1.6960.09 1.6260.09 1.4960.10 1.2860.11 NS
PET plasma/D4 creatinine 0.6360.05 0.6360.04 0.7160.04 0.6960.02 NS
PET D0/D4 glucose 0.3160.04 0.3460.02 0.3460.04 0.3360.03 NS
PET 4 hour ultrafiltration mL 1926100 260666.5 171660.2 123652.2 0.12
Dialysate composition
Median 3.86%/week (range) 0 (0–14) 0 (0–14) 0 (0–14) 2 (0–7)
Median % glucose (range) 1.36 (1.36–2.61) 1.36 (1.36–2.61) 1.36 (1.36–2.61) 1.54 (1.36–2.21)
PET is peritoneum equilibrium test.
in both CAPD and hemodialysis. In this study, the con- duration of action [14]. Unfortunately, muzolimine has
been associated with a neuromyeloencephalopathy, clin-trol group had a decline in CCr of 1.7% and Kt/V of 2.3%
per month, consistent with previous studies (abstract; ically similar to vitamin B12 deficiency in seven patients
with advanced chronic renal failure [15], which limits itsHallett et al, Perit Dial Int 12:124, 1992). This is the first
long-term, large-scale, prospective study to consider the clinical use. A dose of 250 mg furosemide was chosen
in part to reflect historical practice in our unit. Althougheffect of loop diuretics on residual renal function in
CAPD. Previous short-term studies investigating the ef- higher doses of furosemide are used in some centers,
especially in Europe, others believe that such doses arefect of the loop diuretic furosemide in patients on PD
have shown that it is effective even at the low GFR potentially nephrotoxic and should be avoided. By
adopting a dose of 250 mg, it was anticipated that theof a patient with end-stage renal failure, producing a
naturesis and diuresis when used acutely [8, 9]. In addi- study would provided a practical and acceptable clinical
message for the majority of renal units.tion, a previous small study of six patients on PD treated
with muzolimine suggested that the loop diuretic could The key finding of this study is that daily furosemide
administration maintains urine volume over one year ofhave an effect in the longer term [10]. Muzolimine is a
high ceiling loop diuretic with similar effects on the loop PD, by a clinically significant mean difference of 340
mL/day at one year. This was associated with a significantof Henle to furosemide, but with a potentially longer
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difference in sodium excretion, which appears to be the In a healthy population, the proportion of total body
water has been shown to consist of 56% of body weightmechanism behind greater UV, as both groups had simi-
lar free water and electrolyte free water clearances. This [16]. At the start of dialysis, both groups of patients had
similar body composition, with 55% body water in theis consistent with the mechanism of action of furosemide
being on the thick ascending limb of the loop of Henle diuretic group and 52% body water in the control. How-
ever, in the control-treated patients, the proportion ofto decrease absorption of urinary sodium. It is evident
that although sodium excretion is thought to be near max- total body water rose by one year to 64%, whereas in
the diuretic group, it remained constant (52%). Sinceimal with a GFR of less than 10 mL/min, furosemide is
still able to maintain sodium excretion in patients on anthropometric measures were comparable between the
groups, this suggests that the weight gain in the controllong-term PD and to maintain a significant accompa-
nying diuresis. group could be accounted for in large part due to fluid
retention. This is supported by the observation that an-The maintenance of UV in the furosemide-treated
group was also associated with a trend toward an de- thropometric measures did not change during the course
of the study.crease in peritoneal ultrafiltration volume both on over
24-hour measured collection and also on the 4-hour PET This study demonstrates that furosemide can be given
on an intention-to-treat basis to unselected patients onultrafiltration. This is despite comparable peritoneal
membrane characteristics. This finding has been sug- CAPD and that it produces a clinically significant in-
crease in UV without an increase in side effects. Previousgested in previous studies [11], and although the mecha-
nism is not understood, it may well reflect differences in pharmacological studies on furosemide in patients on
CAPD show the total body water clearance of furose-hydration between the two groups. The composition of
the dialysate used by both groups, whether measured by mide is significantly slower than healthy controls (62 vs.
140 mL/min) [17]. Despite this, no adverse events werethe number of 3.86% glucose bags per week or by the
median daily dialysate glucose concentration, was simi- noted during this study. Change in serum urate was com-
parable in both groups, and there were no episodes oflar. This does not appear to be the consequence of under-
reporting of 2.27 or 3.86% glucose dialysate used by symptomatic gout. Interestingly, furosemide given by the
intraperitoneal route to patients on CAPD has pre-patients, as the findings are consistent with an indepen-
dent tally of the bags delivered to each group of patients. viously shown an increase rather than decrease in urinary
urate excretion [18]. Although high doses of furosemideDuring this, the first year on CAPD, both groups used
predominately 1.36% glucose dialysate, with a median are known to be ototoxic, a single dose of 2000 mg given
to eight patients on CAPD was not associated with adaily glucose concentration of 1.54 and 1.36% for the
diuretic and control groups, which were not statistically theoretical ototoxic level (50 mg/L; abstract; van Olden
et al, J Am Soc Nephrol 8:293A, 1987). In addition,different. This general low usage of hyperosmolar glu-
cose dialysate may be the explanation between no detect- furosemide has previously been administered at an intra-
peritoneal dose of 2000 mg/week for three months with-able difference between the two groups, despite differ-
ences in ultrafiltration volume. It is notable that the fluid out audiometric changes [19]. Serum lipids increased in
both groups with time on dialysis, which has been re-balance status of the two groups was different. It remains
a matter of speculation whether the untreated group should ported elsewhere [20], but there appeared to be no dif-
ference between the furosemide-treated and controlhave been advised to use more hypertonic exchanges in
order to achieve the same fluid balance as the furosemide- groups. Therefore, furosemide at 250 mg once per day
was well tolerated and did not produce an increase intreated group.
The second key finding of this study is the rejection unwanted side effects in this large prospective study.
Included in the analysis are three patients in the di-of the widely held belief that regular furosemide adminis-
tration can slow the decline of urinary urea and CCr. The uretic group and two in the control group who became
anuric during the course of the study. Consistent withrate of decline of both solutes was identical in both study
groups and was unaffected by the use of furosemide. Small the findings from short-term diuretic studies, there was
no increase in UV when anuric furosemide-treated pa-differences in the rate of decline of urea and CCr would
not have been detectable with this number of patients. tients were challenged with an additional diuretic. Re-
sults are analyzed on an intention-to-treat basis, includ-However, the study had sufficient power to detect a
clinically significant difference in decline in Kt/V of 0.21 ing these anuric patients, and therefore, the results are
directly applicable to clinical practice. Comparable num-per year with 90% confidence. As both groups had identi-
cal reduction in clearance, a clinically significant differ- bers of patients in each group were lost from PD (trans-
plant, change to HD, and death), although this studyence in the decline of urea and CCr would have been
detected by this study. was not powered to detect significant changes in these
outcomes. Although the proportion of patients with DMBody weight rose in both groups during the study by a
comparable amount (4.3 and 3.0 kg, diuretic vs. control). was higher in the diuretic-treated group, repeat analysis
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4. Lysaght MJ, Vonesh EF, Gotch F, et al: The influence of dialysisexcluding patients with diabetes showed comparable dif-
treatment modality on the decline of remaining renal function.
ferences between groups. The differences observed in ASAIO Trans 37:598–604, 1991
5. Rottembourg J: Residual renal function and recovery of renalthe diuretic group are not therefore influenced the differ-
function in patients treated by CAPD. Kidney Int 43(Supplent etiology of renal failure between the study groups.
40):S106–S110, 1993
In summary, furosemide at 250 mg per day produced 6. Lameire NH, Vanholder R, Veyt D, et al: A longitudinal, five
year survey of urea kinetic parameters in CAPD patients. Kidneya clinically significant preservation in UV over one year
Int 42:426–432, 1992of CAPD. This was associated with a possible improve-
7. Slingeneyer A, Mion C: Five year follow-up of 155 patients treated
ment in body water and was not associated with any by CAPD in European French speaking countries. Perit Dial Int
9(Suppl 1):176, 1989observed increase in side effects. However, furosemide
8. Scarpioni L, Ballocchi S, Bergonzi G, et al: High-dose diureticshad no effect on the rate of decline of urinary urea or
in continuous ambulatory peritoneal dialysis. Perit Dial Bull 2:177–
CCr. These findings lead us to recommend that routine 178, 1982
9. Krediet RT, Douma CE, van Olden RW, et al: Augmenting soluteuse of furosemide is beneficial in new patients starting
clearance in peritoneal dialysis. Kidney Int 54:2218–2225, 1998PD. The caveat would be the lack of apparent benefit 10. Bandiani G, Camaiora E, Nicolini M, et al: Muzolimine in patients
in anuric patients. Although a decrease in ultrafiltration on chronic hemodialysis (HD) and continuous ambulatory perito-
neal dialysis (CAPD). Z Kardiol 74:84–87, 1985is a potential concern, further study is necessary to ad-
11. van Olden RW, Krediet RT, Struijk DG, et al: Measurement ofdress the importance of this finding. residual renal function in patients treated with continuous ambula-
tory peritoneal dialysis. J Am Soc Nephrol 7:745–750, 1996
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